BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

218 related articles for article (PubMed ID: 17947485)

  • 1. A phase I and pharmacologic study of belotecan in combination with cisplatin in patients with previously untreated extensive-stage disease small cell lung cancer.
    Lee DH; Kim SW; Bae KS; Hong JS; Suh C; Kang YK; Lee JS
    Clin Cancer Res; 2007 Oct; 13(20):6182-6. PubMed ID: 17947485
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A phase I study of paclitaxel, etoposide, and cisplatin in extensive stage small cell lung cancer.
    Kelly K; Pan Z; Wood ME; Murphy J; Bunn PA
    Clin Cancer Res; 1999 Nov; 5(11):3419-24. PubMed ID: 10589753
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Multicenter phase 2 study of belotecan, a new camptothecin analog, and cisplatin for chemotherapy-naive patients with extensive-disease small cell lung cancer.
    Lee DH; Kim SW; Suh C; Lee JS; Ahn JS; Ahn MJ; Park K; Na II; Lee JC; Ryoo BY; Yang SH
    Cancer; 2010 Jan; 116(1):132-6. PubMed ID: 19904804
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase II study of combined belotecan and cisplatin as first-line chemotherapy in patients with extensive disease of small cell lung cancer.
    Hong J; Jung M; Kim YJ; Sym SJ; Kyung SY; Park J; Lee SP; Park JW; Cho EK; Jeong SH; Shin DB; Lee JH
    Cancer Chemother Pharmacol; 2012 Jan; 69(1):215-20. PubMed ID: 21691745
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A multicenter phase II study of belotecan, new camptothecin analogue, in patients with previously untreated extensive stage disease small cell lung cancer.
    Kim SJ; Kim JS; Kim SC; Kim YK; Kim YK; Kang JY; Yoon HK; Song JS; Lee SH; Moon HS; Kim JW; Kim KH; Kim CH; Shim BY; Kim HK
    Lung Cancer; 2010 Jun; 68(3):446-9. PubMed ID: 19683359
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A phase I study of 3-day topotecan and cisplatin in elderly patients with small-cell lung cancer.
    Fujiwara K; Ueoka H; Kiura K; Tabata M; Takigawa N; Hotta K; Umemura S; Sugimoto K; Shibayama T; Kamei H; Harita S; Okimoto N; Tanimoto M
    Cancer Chemother Pharmacol; 2006 Jun; 57(6):755-60. PubMed ID: 16208519
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase I study of G3139, a bcl-2 antisense oligonucleotide, combined with carboplatin and etoposide in patients with small-cell lung cancer.
    Rudin CM; Kozloff M; Hoffman PC; Edelman MJ; Karnauskas R; Tomek R; Szeto L; Vokes EE
    J Clin Oncol; 2004 Mar; 22(6):1110-7. PubMed ID: 15020613
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase I and pharmacological study of two schedules of the antifolate edatrexate in combination with cisplatin.
    Laurie SA; Pfister DG; Kris MG; Tong WP; Chronowski G; Pisters KM; Heelan RT; Sirotnak FM
    Clin Cancer Res; 2001 Mar; 7(3):501-9. PubMed ID: 11297240
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A phase I and pharmacological study of amrubicin and topotecan in patients of small-cell lung cancer with relapsed or extensive-disease small-cell lung cancer.
    Shibayama T; Hotta K; Takigawa N; Tada A; Ueoka H; Harita S; Kiura K; Tabata M; Segawa Y; Nogami N; Kuyama S; Shinkai T; Tanimoto M
    Lung Cancer; 2006 Aug; 53(2):189-95. PubMed ID: 16806573
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A phase I trial defining the maximum tolerated systemic exposure of topotecan in combination with Carboplatin and Etoposide in extensive stage small cell lung cancer.
    Gillenwater HH; McCune JS; Lindley C; Faucette S; Shord S; Donahue A; Socinski MA; Stewart CF; Zamboni WC; Kirstein MN; Moore D
    Cancer Invest; 2005; 23(6):511-9. PubMed ID: 16203659
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A randomised phase II study of the efficacy and safety of intravenous topotecan in combination with either cisplatin or etoposide in patients with untreated extensive disease small-cell lung cancer.
    Quoix E; Breton JL; Gervais R; Wilson J; Schramel F; Cardenal F; Ross G; Preston A; Lymboura M; Mattson K
    Lung Cancer; 2005 Aug; 49(2):253-61. PubMed ID: 16022920
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Randomized phase II trial of pemetrexed combined with either cisplatin or carboplatin in untreated extensive-stage small-cell lung cancer.
    Socinski MA; Weissman C; Hart LL; Beck JT; Choksi JK; Hanson JP; Prager D; Monberg MJ; Ye Z; Obasaju CK
    J Clin Oncol; 2006 Oct; 24(30):4840-7. PubMed ID: 17050869
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase I study of tirapazamine plus cisplatin/etoposide and concurrent thoracic radiotherapy in limited-stage small cell lung cancer (S0004): a Southwest Oncology Group study.
    Le QT; McCoy J; Williamson S; Ryu J; Gaspar LE; Edelman MJ; Dakhil SR; Sides SD; Crowley JJ; Gandara DR;
    Clin Cancer Res; 2004 Aug; 10(16):5418-24. PubMed ID: 15328179
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A multicenter phase II study of belotecan, a new camptothecin analogue, as a second-line therapy in patients with small cell lung cancer.
    Rhee CK; Lee SH; Kim JS; Kim SJ; Kim SC; Kim YK; Kang HH; Yoon HK; Song JS; Moon HS; Kim JW; Kim CH; Shim BY; Kim HK; Sun DS; Kim KH
    Lung Cancer; 2011 Apr; 72(1):64-7. PubMed ID: 20832894
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase 1 study of weekly polyethylene glycol-camptothecin in patients with advanced solid tumors and lymphomas.
    Posey JA; Saif MW; Carlisle R; Goetz A; Rizzo J; Stevenson S; Rudoltz MS; Kwiatek J; Simmons P; Rowinsky EK; Takimoto CH; Tolcher AW
    Clin Cancer Res; 2005 Nov; 11(21):7866-71. PubMed ID: 16278410
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase I pharmacokinetic study of S-1 plus cisplatin in patients with advanced gastric carcinoma.
    Ajani JA; Faust J; Ikeda K; Yao JC; Anbe H; Carr KL; Houghton M; Urrea P
    J Clin Oncol; 2005 Oct; 23(28):6957-65. PubMed ID: 16145066
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A phase I trial of carboplatin and etoposide for elderly (>or=75 year-old) patients with small-cell lung cancer.
    Fukuda M; Soda H; Soejima Y; Fukuda M; Kinoshita A; Takatani H; Kasai T; Nagashima S; Kawabata S; Doi S; Kohno S; Oka M
    Cancer Chemother Pharmacol; 2006 Nov; 58(5):601-6. PubMed ID: 16463061
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase I dose-finding study and a pharmacokinetic/pharmacodynamic analysis of the neutropenic response of intravenous diflomotecan in patients with advanced malignant tumours.
    Trocòniz IF; Garrido MJ; Segura C; Cendrós JM; Principe P; Peraire C; Obach R
    Cancer Chemother Pharmacol; 2006 Jun; 57(6):727-35. PubMed ID: 16261364
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Preliminary results of a phase I study with MTA (LY231514) in combination with cisplatin in patients with solid tumors.
    Thödtmann R; Depenbrock H; Blatter J; Johnson RD; van Oosterom A; Hanauske AR
    Semin Oncol; 1999 Apr; 26(2 Suppl 6):89-93. PubMed ID: 10598561
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A Phase I and pharmacological study of the platinum polymer AP5280 given as an intravenous infusion once every 3 weeks in patients with solid tumors.
    Rademaker-Lakhai JM; Terret C; Howell SB; Baud CM; De Boer RF; Pluim D; Beijnen JH; Schellens JH; Droz JP
    Clin Cancer Res; 2004 May; 10(10):3386-95. PubMed ID: 15161693
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.